Cefoperazone/Sulbactam In The Treatment Of Serious Intra-Abdominal And Hepatobiliary Infections.

NCT00463762 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2011-04-22

No results posted yet for this study

Summary

The primary objective is to collect data on treatment outcomes (clinical and microbiological cure), safety and tolerability of treatment with cefoperazone/sulbactam in patients with serious intra-abdominal and hepatobiliary infections in Slovakia.

Conditions

  • Abscess, Intra-Abdominal
  • Cholecystitis
  • Wound Infections
  • Peritonitis
  • Appendicitis

Interventions

DRUG

CP-75385-02 Cefoperazone/sulbactam

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-05-31

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00463762 on ClinicalTrials.gov